Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis
NCT05388838 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2025-03-03
Summary
Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor. These diseases can result in significant vision loss and account for 10% of all blindness in developed countries, and up to 25% in developing countries. The main difficulty in this pathology is to make the etiological diagnosis, which then allows a specific treatment of the disease. The main etiologie are inflammatory or infectious (sarcoidosis, tuberculosis) but other cancerous etiologies are possible and are of more complicated diagnosis.
Vitreoretinal lymphoma is a subtype of central nervous system lymphoma, which is generally associated with a poor prognosis. It is a diffuse non-Hodgkin's lymphoma, with large B cells. It can be primary ocular (Primary Intra-Ocular Lymphoma - LIOP), without brain involvement, but can also be secondary to central nervous system involvement, which explains the poor prognosis of the disease. Approximately 50-90% of LIOP develop brain involvement within 1-2 years of diagnosis, which encourages early diagnosis to avoid brain involvement as much as possible.
The main obstacle to rapid diagnosis is the difficulty of identifying LIOP. Indeed, the clinical symptoms of this rare disease are often identical to classical uveitis, and the diagnostic means to detect it are invasive and require a trained ophthalmologist and hematologist team. LIOP diagnostic tests are often delay in the management of uveitis and lead to diagnostic erraticity that can last between 4 to 40 months.
The INSERM U1183 unit is developing a diagnostic technology for lymphomas based on the analysis of blood NK cells and their phenotypes including those acquired by trogocytosis (WO/2016/005548).
A rapid, simple, minimally invasive LIOP test using this technology could therefore be propose to all patients presenting with uveitis and whose clinical criteria could match those of LIOP.
The research hypothesis is : Could the diagnostic wandering of patients with primary intraocular lymphoma be reduced by a rapid blood test for NK cell phenotype of patients with uveitis? Following a simple blood test, a rapid LIOP test, using this diagnostic technology, could therefore be proposed to all patients with uveitis and clinical criteria (age, intermediate and posterior location of the uveitis) corresponding to those of LIOP.
The primary objective of this study is to compare the phenotype of circulating NK cells of patient with untreated intraocular lymphoma versus the phenotype of patient with non-cancerous uveitis.
Conditions
- Uveitis
- Lymphoma
- NK-Cell Lymphoma
Interventions
- BIOLOGICAL
-
Blood sample
Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-01
- Primary Completion
- 2025-12-01
- Completion
- 2025-12-01
Countries
- France
Study Locations
More Related Trials
-
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
NCT02656381 ·Status: COMPLETED
-
Uveitis Gene-Expression Profiling
NCT00874471 ·Status: COMPLETED
-
Evaluation of a Standardized Strategy for Uveitis Etiological Diagnosis
NCT01162070 ·Status: COMPLETED ·Phase: NA
-
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
NCT05385757 ·Status: ACTIVE_NOT_RECRUITING
-
Immune Indicators of Uveitis
NCT00089739 ·Status: COMPLETED
-
Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases
NCT00357071 ·Status: COMPLETED
-
A Clinical Trial of Infliximab for Uveitis
NCT00273390 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy
NCT00468871 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Screening for NEI Clinical Studies
NCT00001734 ·Status: COMPLETED
-
Daclizumab and Sirolimus to Treat Uveitis
NCT00078689 ·Status: COMPLETED ·Phase: PHASE1
-
Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab
NCT00605943 ·Status: COMPLETED
-
Lucentis for Inflammatory Macular Edema Trial
NCT00498355 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
NCT00326508 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
NCT01138657 ·Status: COMPLETED ·Phase: PHASE3
-
Leflunomide to Treat Uveitis
NCT00001863 ·Status: COMPLETED ·Phase: PHASE2
-
BIIB033 In Acute Optic Neuritis (AON)
NCT01721161 ·Status: COMPLETED ·Phase: PHASE2
-
Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
NCT02879084 ·Status: COMPLETED
-
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
NCT00070759 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)
NCT04117698 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
NCT00415506 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
NCT02169648 ·Status: UNKNOWN ·Phase: NA
-
Microbiome as a ThErapeutic Response Biomarker
NCT04721743 ·Status: WITHDRAWN
-
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
NCT01526889 ·Status: COMPLETED ·Phase: PHASE2
-
Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
NCT02218177 ·Status: COMPLETED
-
Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
NCT00043667 ·Status: COMPLETED ·Phase: PHASE2